Documentos de Olloquequi J. | REDI

Regresar

Mostrando 10 resultados de: 18

Filtros aplicados

Área de conocimiento: "Neurología"

Subtipo de publicación

Publisher

Frontiers in Aging Neuroscience(2)

Frontiers in Bioscience - Landmark(2)

Molecular Neurobiology(2)

Biomedicine and Pharmacotherapy(1)

Cell and Bioscience(1)

Área temáticas

Enfermedades(16)

Fisiología humana(8)

Farmacología y terapéutica(7)

Medicina y salud(4)

Ginecología, obstetricia, pediatría, geriatría(3)

Área de conocimiento

Neuropsicología(6)

Biología del desarrollo(2)

Medicina interna(2)

Año de Publicación

Origen

Palabras Claves

Alzheimer's disease(4)

neuroinflammation(4)

Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia

Abstract: Benzodiazepines (BZDs) and Z-drugs are compounds widely prescribed in medical practice due to their

Palabras claves:

Alzheimer's disease, benzodiazepines, COGNITION, dementia, RISK FACTORS

Antoni Camins, Auladell C., Bulló M., Busquets O., Cano A., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Zárate C.B.

Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice

Abstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´s

Palabras claves:

Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaques

Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.

Dexibuprofen prevents neurodegeneration and cognitive decline in APPswe/PS1dE9 through multiple signaling pathways

Abstract: The aim of the present study is to elucidate the neuronal pathways associated to NSAIDs causing a re

Palabras claves:

Alzheimer's disease, APPswe/PS1dE9, Dexibuprofen, hippocampus, insulin receptor, Memory impairment, Mitochondria, Tau

Antoni Camins, Auladell C., Busquets O., Ettcheto M., Folch J., García M.L., Olloquequi J., Pallás M., Pons L., Sanchez-Lopez E., Zárate C.B.

Current Research Therapeutic Strategies for Alzheimer's Disease Treatment

Abstract: Alzheimer's disease (AD) currently presents one of the biggest healthcare issues in the developed co

Palabras claves:

Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., García M.L., Olloquequi J., Petrov D., Sanchez-Lopez E., Zárate C.B.

Excitotoxicity in the pathogenesis of neurological and psychiatric disorders: Therapeutic implications

Abstract: Neurological and psychiatric disorders are leading contributors to the global disease burden, having

Palabras claves:

Alzheimer’s disease, Autism Spectrum Disorder, Depression, glutamate, stroke

Antoni Camins, Auladell C., Binvignat O., Cornejo-Córdova E., Olloquequi J., Soriano F.X., Verdaguer E.

Neuroprotective Effects of the Absence of JNK1 or JNK3 Isoforms on Kainic Acid-Induced Temporal Lobe Epilepsy-Like Symptoms

Abstract: The activation of c-Jun-N-terminal kinases (JNK) pathway has been largely associated with the pathog

Palabras claves:

c-Jun N-terminal kinase, Excitotoxicity, hippocampus, inflammation, Kainic acid, Knockout mice, Neurodegeneration, neuroprotection

Antoni Camins, Auladell C., Castro-Torres R.D., De Lemos M.L., Folch J., Junyent F., Olloquequi J., Verdaguer E., Zárate C.B.

Masitinib for the treatment of mild to moderate Alzheimer's disease

Abstract: Alzheimer's disease (AD) is a degenerative neurological disorder that is the most common cause of de

Palabras claves:

ALZHÉIMER, inflammation, masitinib, Neurodegeneration, Tau

Abad S., Antoni Camins, Auladell C., Ettcheto M., Folch J., Lazarowski A., Miguel Marin, Olloquequi J., Pedros I., Petrov D., Zárate C.B.

Impact of New Drugs for Therapeutic Intervention in Alzheimer’s Disease

Abstract: The increases in population ageing and growth are leading to a boosting in the number of people livi

Palabras claves:

clinical studies, dementia, neuroinflammation, novel therapies, synapses

Antoni Camins, Auladell C., Cano A., Carrasco M., Espinosa T., Ettcheto M., Folch J., Gudiño-Cabrera G., Olloquequi J., Sanchez-Lopez E., Ureña-Guerrero M.E., Verdaguer E., Zárate C.B.

Memantine for the treatment of dementia: A review on its current and future applications

Abstract: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the presence in the brain

Palabras claves:

Alzheimer's disease, Amyloid-protein, Extrasynaptic N-Methyl-D-aspartate receptor, Memantine, Tau protein

Antoni Camins, Auladell C., Busquets O., Casadesús G., Castro-Torres R.D., Ettcheto M., Folch J., García M.L., Olloquequi J., Pelegrí Gabalda C., Sanchez-Lopez E., Verdaguer E., Vilaplana J., Zárate C.B.

Peroxisomal Proliferator-Activated Receptor β/δ Deficiency Induces Cognitive Alterations

Abstract: Peroxisome proliferator-activated receptor β/δ (PPARβ/δ), the most PPAR abundant isotype in the cent

Palabras claves:

dendritic spines, high-fat diet, insulin signaling, Memory impairment, neuroinflammation, PPARβ/δ, synapsis, T2DM

Antoni Camins, Auladell C., Busquets O., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Olloquequi J., Parcerisas A., Sanchez-Lopez E., Vázquez-Carrera M., Verdaguer E., Wahli W.